Genfit S.A. | Balance Sheet

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
20,922.00
72,005.00
60,111.00
152,277.00
273,820.00
207,240
Total Accounts Receivable
4,950.60
6,702.20
6,007.00
8,394.00
7,955.00
8,794
Inventories
167.00
248.00
28.00
14.00
4.00
4
Other Current Assets
1,059.40
4,857.80
607.00
1,311.00
1,761.00
2,078
Total Current Assets
27,099.00
83,813.00
66,753.00
161,996.00
283,572.00
218,116
Net Property, Plant & Equipment
1,000.00
1,333.00
1,324.00
3,010.00
6,324.00
7,764
Total Investments and Advances
-
-
-
-
729.00
-
Long-Term Note Receivable
113.60
136.80
289.00
188.00
1,921.00
259
Intangible Assets
130.00
161.00
563.00
668.00
636.00
796
Other Assets
808.40
922.20
216.00
243.00
-
2,543
Total Assets
29,151.00
86,366.00
69,145.00
166,105.00
293,183.00
229,478
ST Debt & Current Portion LT Debt
758.50
887.70
1,218.00
1,241.00
3,163.00
Accounts Payable
5,454.00
5,900.00
5,275.00
13,341.00
19,053.00
Income Tax Payable
162.50
357.80
156.00
-
241.00
Other Current Liabilities
2,700.00
3,245.50
1,964.00
2,980.00
4,649.00
Total Current Liabilities
9,075.00
10,391.00
8,613.00
17,562.00
27,106.00
Long-Term Debt
1,397.00
1,270.00
4,482.00
5,004.00
160,589.00
Provision for Risks & Charges
412.00
614.00
742.00
848.00
936.00
Other Liabilities
4,174.00
3,662.00
5.00
3.00
2.00
Total Liabilities
15,058.00
15,937.00
13,842.00
23,417.00
188,633.00
Common Equity (Total)
14,093.00
70,429.00
55,303.00
142,688.00
104,229.00
Total Shareholders' Equity
14,093.00
70,429.00
55,303.00
142,688.00
104,229.00
Total Equity
14,093.00
70,429.00
55,303.00
142,688.00
104,229.00
Liabilities & Shareholders' Equity
29,151.00
86,366.00
69,145.00
166,105.00
293,183.00

About Genfit

View Profile
Address
Parc Eurasante
Loos Nord-Pas-de-Calais 59120
France
Employees -
Website http://www.genfit.com
Updated 07/08/2019
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. Its research and development efforts are focused on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver.